SUNDAY, June 2 (HealthDay News) -- A drug already used for
advanced kidney and liver cancers may help slow the progression of
thyroid cancers that do not respond to standard treatment, a new
clinical trial finds.
Researchers found that the drug, called sorafenib (Nexavar),
taken as a pill, nearly doubled the length of time that patients
remained progression-free -- from about six months to 11
It's not a cure, and no one knows yet whether sorafenib can
ultimately extend people's lives. But experts said the findings
offer some hope to a group of patients who currently lack good
"If we can control the disease, and do it with tolerable toxicity, that's a good thing," said Dr. Gregory Masters, a medical oncologist who was not involved in the research.
In general, thyroid cancer is a highly curable disease. But
about 10 percent of patients do not respond to the mainstays of
treatment: surgery and radioactive iodine, a form of radiation
taken by liquid or pill.
On average, those patients survive for another two to three
years, said Dr. Marcia Brose of the University of Pennsylvania in
Philadelphia, the lead researcher on the new study.
"We've taken a big step with this study," Brose said. "The message for these patients is that there is hope."
The findings come from an international trial of 417 patients
with thyroid cancer that had failed to respond to standard
treatment and had spread beyond the thyroid -- a gland in the neck
that secretes metabolism-controlling hormones.
About half of the patients were randomly assigned to take
sorafenib, while the rest were given inactive placebo pills.
Overall, 42 percent of sorafenib patients had no cancer progression
for at least six months, versus one-third of placebo patients. And
12 percent of patients on the drug saw their tumors shrink by 30
percent or more -- versus 0.5 percent of the placebo group.
Brose is scheduled to present the findings Sunday at the annual
meeting of the American Society of Clinical Oncology, in Chicago.
She is a paid consultant to Bayer HealthCare and Onyx
Pharmaceuticals, which co-market Nexavar and funded the trial.
Because this study was presented at a medical meeting, the data
and conclusions should be viewed as preliminary until published in
a peer-reviewed journal.
Sorafenib has not yet won approval from the U.S. Food and Drug
Administration (FDA) to treat thyroid cancer. If it does, it would
be the first new drug for the disease in almost 40 years.
The thyroid is a gland in the neck that secretes hormones
involved in metabolism. Thyroid cancer, which is diagnosed in about
60,000 Americans each year, has a high cure rate -- a fact that, in
a way, has worked against the few patients with resistant tumors,
"It's given the misperception that this disease is all wrapped up," she said.
Still, it's not that there has been no research into ways to
help patients with resistant thyroid cancer, Brose pointed out. But
the chemotherapy drugs that have been tried have met with little
success. Doxorubicin was the last drug approved for advanced
thyroid cancer, back in 1974, but doctors rarely use it because its
benefits are minor and its side effects are severe.
But now there are newer, so-called targeted chemotherapy drugs
that are designed to zero in on tumor cells and spare more healthy
cells. Sorafenib is one of those; it's in a class called kinase
inhibitors, and it blocks certain enzymes that help feed the growth
and spread of tumor cells.
"We're excited to have an option for these patients that has less toxicity," said Masters, a spokesperson for ASCO who specializes in cancers of the throat and chest. And because it's an oral medication, he added, it spares people from having to come to the hospital for treatment.
In the trial, the most common side effects were skin reactions
on the hands and feet, diarrhea, hair loss, fatigue and weight loss
-- which is what's been seen with the drug in other cancers. "The
side effects were tolerable to patients," Brose said.
There are still unanswered questions -- including whether
sorafenib gives patients a shot at a longer life. "We won't know
that for a few years," Brose said. And there's no way to predict
whether or when the FDA will clear the drug for thyroid cancer.
Because sorafenib is approved for other cancers, doctors can use
it on an "off-label" basis for thyroid cancer. However, that makes
insurance coverage a thornier issue, and the drug costs several
thousand dollars a month.
"Most people would not be able to pay for it on their own," Masters said. Insurance companies may pay, he noted, but doctors need to work it out with health plans on a case-by-case basis.
If the FDA approves sorafenib specifically for thyroid cancer,
that would make insurance coverage much easier for patients,
He added that sorafenib is not the only drug under study for
resistant cases of thyroid cancer; other types of newer, targeted
medications are being tested.
Study author Brose said that should be welcome news to a group
of patients who may have thought their disease was forgotten.
"There are options out there," she said, "and researchers are
Learn more about
thyroid cancerfrom the American Cancer
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.